Literature DB >> 10071681

Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage.

E Tachibana1, T Harada, M Shibuya, K Saito, M Takayasu, Y Suzuki, J Yoshida.   

Abstract

In this pilot study we treated cerebral vasospasm in patients with subarachnoid haemorrhage to assess intra-arterial fasudil hydrochloride. We analysed effects of intra-arterial infusion on angiographically evident cerebral vasospasm in 10 patients including 3 with symptoms of vasospasm. Over 10 to 30 min 15 to 60 mg was administered via the proximal internal carotid artery or vertebral artery following standard angiography, without superselective techniques. A total of 24 arterial territories (21 internal carotid, 3 vertebral) were treated. Angiographic improvement of vasospasm was demonstrated in 16 arterial territories (local dilation in 2, diffuse dilation in 14) in 9 patients. In 2 symptomatic patients, intra-arterial fasudil hydrochloride was associated with resolution of symptoms without sequelae. In the third symptomatic patient the benefit of fasudil hydrochloride was only temporary, and a large cerebral infarction occurred. All asymptomatic patients showed no progression of angiographic to symptomatic vasospasm after treatment with intra-arterial fasudil hydrochloride. No adverse effect was encountered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071681     DOI: 10.1007/s007010050260

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  24 in total

1.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Intracranial hemorrhage after intra-arterial administration of fasudil for treatment of cerebral vasospasm following subarachnoid hemorrhage: a serious adverse event.

Authors:  Masahiro Ishihara; Kazunori Yamanaka; Shin Nakajima; Mami Yamasaki
Journal:  Neuroradiology       Date:  2011-03-24       Impact factor: 2.804

3.  Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery.

Authors:  T J Batchelor; J R Sadaba; A Ishola; P Pacaud; C M Munsch; D J Beech
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.

Authors:  Siu-Lung Chan; Marilyn J Cipolla
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-30       Impact factor: 6.200

5.  Blast-induced phenotypic switching in cerebral vasospasm.

Authors:  Patrick W Alford; Borna E Dabiri; Josue A Goss; Matthew A Hemphill; Mark D Brigham; Kevin Kit Parker
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-15       Impact factor: 11.205

Review 6.  Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: a comprehensive review of the literature.

Authors:  Guilherme Dabus; Raul G Nogueira
Journal:  Interv Neurol       Date:  2013-10

7.  Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.

Authors:  Miki Fujimura; Jin-Yang Joo; Jong-Soo Kim; Motonori Hatta; Yoshinari Yokoyama; Teiji Tominaga
Journal:  Cerebrovasc Dis       Date:  2017-05-03       Impact factor: 2.762

8.  Intra-arterial colforsin daropate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Satoshi Suzuki; Osamu Ito; Tetsuro Sayama; Katsuya Goto
Journal:  Neuroradiology       Date:  2009-12-02       Impact factor: 2.804

9.  ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation.

Authors:  Jieya Shao; William J Welch; Marc I Diamond
Journal:  FEBS Lett       Date:  2008-04-16       Impact factor: 4.124

10.  Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of rho-kinase.

Authors:  Lin Huang; Zhi He; Lianjun Guo; Hongxing Wang
Journal:  Cell Mol Neurobiol       Date:  2007-06-07       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.